Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jaguar Health, Inc.JAGX · Entity 8387 | Chief Financial Officer | December 11, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jaguar Health, Inc.
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,911 |
Reported balance
After 2025-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 11,740 · Balance 11,911 F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. F4: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2035-12-11 | Direct | 11,740 |
Reported balance
After 2025-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-11 · Grant · Acquired 11,740 · Balance 11,740 F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F5: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
F4: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
F5: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2025 Filed Dec 15, 2025 22:46 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 11,740 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001193125-25-319495 · ownership.xml · derivative · entry 2 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,740 Underlying: Common Stock · 11,740 shares Expires 2035-12-11 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F5 · derivative.exercise_date: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 22:46 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 11,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-319495 · ownership.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,911 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. F4 · balance_after: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:10 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | PurchaseWarrant to Purchase Common Stock · Derivative | 5,400 | Not disclosed Strike: $5.43 | Not disclosed |
DisclosureSEC source: 0000950170-25-049802 · ownership.xml · derivative · entry 2 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires 2030-03-31 F2 · price: As an inducement to enter into the Purchase Agreement, the reporting person received a warrant (the "Warrant") to purchase up to 5,400 shares of Common Stock with an exercise price of $5.43 per share. The Warrant is exercisable immediately upon issuance and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:10 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | PurchaseConvertible Promissory Note · Derivative | 5,400 | $30,000.00 Strike: $5.56 | $162,000,000.00 |
DisclosureSEC source: 0000950170-25-049802 · ownership.xml · derivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires not disclosed F1 · derivative.exercise_date: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 5,400 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. F1 · derivative.expiration_date: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 5,400 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 01:58 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 34,240 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-24-114194 · ownership.xml · derivative · entry 3 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,240 Underlying: Common Stock · 34,240 shares Expires 2034-10-08 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024. F5 · derivative.exercise_date: The options will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 01:58 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 4,280 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-114194 · ownership.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,297 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024. F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest in three equal annual installments beginning on October 8, 2025. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice. F4 · balance_after: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the " Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:02 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionRestricted stock units · Derivative | 431 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063897 · tm2414996-1_4seq1.xml · derivative · entry 3 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431 Underlying: Common Stock · 431 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 97,025 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F3 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 97,025 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:02 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 431 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-063897 · tm2414996-1_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| April 05, 2024 Filed Apr 17, 2024 20:31 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 60 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048343 · tm2411853-1_4seq1.xml · derivative · entry 3 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 40,625 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 40,625 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Read SEC document |
| April 05, 2024 Filed Apr 17, 2024 20:31 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 60 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-048343 · tm2411853-1_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 20:48 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 142,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-091451 · tm2320633-4_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,745 Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:02 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionRestricted stock units · Derivative | 431 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-062743 · tm2316214-4_4seq1.xml · derivative · entry 3 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862 Underlying: Common Stock · 431 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 97,025 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F3 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 97,025 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:02 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 431 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-062743 · tm2316214-4_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| April 05, 2023 Filed Apr 20, 2023 21:19 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 60 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-047881 · tm2311973-5_4seq1.xml · derivative · entry 2 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60 Underlying: Common Stock · 60 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 40,625 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 40,625 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Read SEC document |
| April 05, 2023 Filed Apr 20, 2023 21:19 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 60 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-047881 · tm2311973-5_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 02:10 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 14,294 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001104659-22-130631 · tm2233639-1_4seq1.xml · derivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,294 shares Expires 2031-04-05 F2 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. F1 · balance_after: The option was cancelled by mutual agreement of the reporting person and Jaguar Health, Inc. The reporting person received $300 as consideration for the cancellation. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:35 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-043247 · tm2211739-1_4seq1.xml · derivative · entry 2 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,028 Underlying: Common Stock · 4,513 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 40,625 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 40,625 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:35 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 4,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-043247 · tm2211739-1_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:32 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 97,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-040397 · tm2210715-6_4seq1.xml · derivative · entry 2 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,025 Underlying: Common Stock · 97,025 shares Expires not disclosed F2 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · date: The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022. F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| September 13, 2021 Filed Mar 31, 2022 01:32 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | PurchaseCommon Stock | 7,968 | $2.51 | $19,999.68 |
DisclosureSEC source: 0001104659-22-040397 · tm2210715-6_4seq1.xml · nonDerivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,968 F1 · ownership.nature: Securities held directly by the Peter & Carol Lizak Revocable Trust. Ms. Lizak, by virtue of her position as a co-trustee and beneficiary of such trust and her sharing of voting and investment control over the securities held by the trust with her spouse, may be deemed to beneficially own the securities held by the Peter & Carol Lizak Trust for purposes of Section 16. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:23 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 40,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-047567 · a4.xml · derivative · entry 2 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Common Stock · 40,625 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021. F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice. F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:23 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 81,250 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001104659-21-047567 · a4.xml · derivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires 2031-04-05 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021. F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 01:54 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-20-037937 · a4.xml · derivative · entry 1 Lizak Carol R. · CIK 0001785794 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-20 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on March 20, 2020. F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.